Home/Pipeline/MK-7240

MK-7240

Ulcerative Colitis

Phase 2b/3Active, Ongoing

Key Facts

Indication

Ulcerative Colitis

Phase

Phase 2b/3

Status

Active, Ongoing

Company

Merck

About Merck

Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.

View full company profile

Therapeutic Areas

Oncology Vaccines Immunology Cardiometabolic Infectious Diseases Neuroscience

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BEN-8744	BenevolentAI	Phase 1b	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
MB310	Microbiotica	Phase 1b	Active